Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Specific peripheral B cell tolerance defects in patients with multiple sclerosis.
Transverse myelitis -- a review of the presentation, diagnosis, and initial management.
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
Combination Treatment of Interferon β-1b and Warfarin for a Patient With Baló's Concentric Sclerosis and Antiphospholipid Syndrome.
Drak2 Does Not Regulate TGF-β Signaling in T Cells.
Stress signaling etches heritable marks on chromatin.
Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome.
[Intractable vomiting as first manifestation of neuromyelitis Optica.]
Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
Epidemiology of Neuromyelitis Optica in the United States: A Multicenter AnalysisEpidemiology of NMO.
Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica.
Treatment with 4-aminopyridine improves upper limb tremor of a patient with multiple sclerosis: a video case report.
Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial.
Differential effects of fingolimod on B-cell populations in multiple sclerosis.
Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer.
Phase II Cladribine Add-on to Interferon-beta (IFN-b) Therapy in MS Subjecs With Active Disease (ONWARD)
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies.
Gut microbiota composition and relapse risk in pediatric MS: A pilot study.
Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection.
Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment.
Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis.
Overcoming barriers in progressive multiple sclerosis research.
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Pages